Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Caveolin-1–Nuclear factor erythroid 2-related factor 2 (CAV1–Nrf2) signaling axis is a critical regulatory mechanism that links plasma membrane structural integrity with the cellular antioxidant response [PubMed: 22416018]. Caveolin-1, a primary scaffolding protein of caveolae, directly interacts with the transcription factor Nrf2, typically sequestering it in the cytoplasm and inhibiting its ability to drive the expression of cytoprotective genes [UniProt: P14416]. This interaction is mediated by the caveolin-scaffolding domain (CSD) of CAV1 and the Nrf2-ECH homology (Neh) domains of Nrf2 [PubMed: 28636914]. Dysregulation of this axis is implicated in various pathologies; for instance, loss of CAV1 can lead to constitutive Nrf2 activation, which may promote chemoresistance in cancer cells, while CAV1 overexpression can suppress Nrf2, exacerbating oxidative damage in conditions like pulmonary fibrosis and cardiovascular disease [NCBI: PMC4688118]. Therapeutic interventions targeting this axis generally utilize Nrf2 activators, such as Sulforaphane or Bardoxolone methyl, to disrupt inhibitory complexes and restore redox homeostasis [PubMed: 23972477]. Understanding the balance within this axis is crucial for developing targeted therapies that address oxidative damage without inadvertently promoting tumor cell survival.
The mechanism of action involves the pharmacological disruption of the inhibitory interaction between Caveolin-1 and Nrf2, or the modification of Keap1, leading to the stabilization and nuclear translocation of Nrf2 [PubMed: 22416018]. Once in the nucleus, Nrf2 binds to the Antioxidant Response Element (ARE) in the promoter regions of target genes, inducing the transcription of antioxidant and phase II detoxification enzymes such as Heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1) [NCBI: PMC4688118].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Caveolin-1–Nuclear factor erythroid 2-related factor 2 signaling axis (CAV1–Nrf2 axis).